# US 2005/0069561 A1 · Escape mutants of newcastle disease virus as marker vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0069561 A1
- Document ID: US20050069561A1
- Status: Published application
- Kind: A1
- Application number: 10/990,204
- Filed: 2004-11-16
- Published: 2005-03-31
- Earliest claimed: 2002-12-06
- Assignees: Wyeth
- Inventors: Harmen Greerligs; Ian Brown; Dennis Alexander; Michael Collins
- Web page: https://patentgrep.com/patent/US20050069561A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/17: Newcastle disease virus
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2760/18122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/125: Newcastle disease virus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain. The mutant immunogen lacks the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. Reagent kits and assay methods help to distinguish vaccinated members of a poultry flock from those that may have been infected with wild-type Newcastle Disease virus.

## Claims

### Claim 1

A vaccine against Newcastle Disease virus, comprising about 100-109 EID50 of a mutant immunogen from the NDW strain of the Newcastle Disease virus, wherein said mutant immunogen lacks the antigenic binding site on the F glycoprotein recognized by the monoclonal antibody designated mAb 54.

### Claim 2 (depends on 1)

The vaccine as claimed in claim 1, wherein said mutant immunogen is serially passaged.

### Claim 3 (depends on 2)

The vaccine as claimed in claim 2, wherein said serial passaging occurs in poultry eggs.

### Claim 4 (depends on 3)

The vaccine as claimed in claim 3, wherein said serial passaging comprises at least about two and up to about ten serial passages.

### Claim 5 (depends on 4)

The vaccine as claimed in claim 4, wherein said serial passaging comprises about four to about six serial passages.

### Claim 6 (depends on 1)

The vaccine as claimed in claim 1, wherein said mutant immunogen is identified as p. 13, and is deposited at the CNCM in Paris, France under accession number I-2928.

### Claim 7

An immunogen of Newcastle Disease virus having the immunogenic characteristics of the strain deposited with the CNCM under accession number #I-2928.

### Claim 8

A method of protecting a poultry animal from Newcastle Disease, which comprises administering to said animal about 100-109 EID50 of a mutant immunogen from the NDW strain of the Newcastle Disease virus, wherein said mutant immunogen lacks the antigenic binding site on the F glycoprotein recognized by the monoclonal antibody mAb 54.

### Claim 9 (depends on 8)

The method of claim 8, wherein about 104-109 EID50 of mutant immunogen is administered.

### Claim 10

A method of generating a Newcastle Disease virus mutant immunogen useful in a vaccine against Newcastle Disease, which comprises growing Newcastle Disease virus in the presence of the monoclonal antibody designated mAb 54, such that said mutant immunogen develops and grows in the presence of said monoclonal antibody and is not neutralized by said monoclonal antibody.

### Claim 11 (depends on 10)

The method of claim 10, wherein said Newcastle Disease virus is the NDW strain.

### Claim 12 (depends on 11)

The method of claim 11, wherein said virus is grown in embryonated poultry eggs.

### Claim 13

A mutant immunogen of Newcastle Disease virus wherein the F glycoprotein on said virus is derived from the partial nucleotide sequence shown in Seq. ID No. 1, and further wherein said glycoprotein lacks the binding site for monoclonal antibody designated mAb 54.

### Claim 14

An immunogen of Newcastle Disease virus having the immunogenic characteristics of the mutant immunogen with the amino acid sequence shown in Seq. ID No. 2.

### Claim 15

A mutant immunogen of Newcastle Disease virus in which the amino acid serine is replaced by arginine at position 157.
